LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Закрыт

СекторЗдравоохранение

3.08 0.33

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.04

Макс.

3.19

Ключевые показатели

By Trading Economics

Доход

-15M

-40M

Продажи

8.2M

50M

Рентабельность продаж

-80.43

Сотрудники

435

EBITDA

-19M

-42M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+29.87% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

11 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

7.8M

1.1B

Предыдущая цена открытия

2.75

Предыдущая цена закрытия

3.08

Новостные настроения

By Acuity

50%

50%

167 / 350 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

25 мар. 2026 г., 20:20 UTC

Приобретения, слияния, поглощения

Infosys Agrees to Acquire Stratus

25 мар. 2026 г., 23:58 UTC

Отчет

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25 мар. 2026 г., 23:58 UTC

Отчет

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25 мар. 2026 г., 23:57 UTC

Отчет

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25 мар. 2026 г., 23:57 UTC

Отчет

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25 мар. 2026 г., 23:56 UTC

Отчет

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25 мар. 2026 г., 23:56 UTC

Отчет

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25 мар. 2026 г., 23:41 UTC

Обсуждения рынка

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25 мар. 2026 г., 23:41 UTC

Отчет

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25 мар. 2026 г., 23:34 UTC

Обсуждения рынка
Главные новостные события

Gold Declines on Possible Technical Correction -- Market Talk

25 мар. 2026 г., 22:08 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

25 мар. 2026 г., 22:08 UTC

Обсуждения рынка

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25 мар. 2026 г., 22:07 UTC

Отчет

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25 мар. 2026 г., 22:07 UTC

Отчет

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25 мар. 2026 г., 22:07 UTC

Отчет

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25 мар. 2026 г., 22:07 UTC

Отчет

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25 мар. 2026 г., 22:07 UTC

Отчет

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25 мар. 2026 г., 21:58 UTC

Обсуждения рынка

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25 мар. 2026 г., 21:37 UTC

Обсуждения рынка

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25 мар. 2026 г., 21:14 UTC

Приобретения, слияния, поглощения

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25 мар. 2026 г., 21:13 UTC

Приобретения, слияния, поглощения

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25 мар. 2026 г., 21:12 UTC

Приобретения, слияния, поглощения

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25 мар. 2026 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

25 мар. 2026 г., 20:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Health Care Roundup: Market Talk

25 мар. 2026 г., 20:33 UTC

Приобретения, слияния, поглощения

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25 мар. 2026 г., 20:31 UTC

Отчет

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25 мар. 2026 г., 20:15 UTC

Приобретения, слияния, поглощения

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25 мар. 2026 г., 20:15 UTC

Приобретения, слияния, поглощения

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25 мар. 2026 г., 20:15 UTC

Приобретения, слияния, поглощения

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25 мар. 2026 г., 20:15 UTC

Приобретения, слияния, поглощения

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Сравнение c конкурентами

Изменение цены

Maravai LifeSciences Holdings Inc (Class A) Прогноз

Целевая цена

By TipRanks

29.87% рост

Прогноз на 12 месяцев

Средняя 4 USD  29.87%

Максимум 5 USD

Минимум 3 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Maravai LifeSciences Holdings Inc (Class A) на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

6 ratings

3

Покупка

3

Удержание

0

Продажа

Техническая оценка

By Trading Central

2.02 / 2.115Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Strong Bullish Evidence

Долгосрочная

No Evidence

Настроения

By Acuity

167 / 350Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat